SNTA looks good heading into ASCO, what else are you buying/holding?
Yes, I know the risks here with PPHM!
But, overall, I view their cancer drug in the same light as ours (Synta's) and Thresholds...
All three are first or best in class new cancer drugs with potentially broad usage for many cancer types and therefore massive potential.
I put Ganetespib's odds as the best of the three--next is Threshold's TH-302, and PPHM's drug (bavi) is at the bottm